

## Keyword Index for Volume 91

- 14-3-3  $\sigma$  1131  
15d-PGJ<sub>2</sub> 633, 1074  
[<sup>18</sup>F]FHPG 2079  
[<sup>18</sup>F]FMISO-PET 1947  
1p36 1119  
3,3'-diindolylmethane 1358  
4HPR 1821  
5-fluorouracil 618, 1428, 1442, 1466  
5-FU 1447  
5-iodo-2'-deoxyuridine 366  
667 COUMATE 1399  
8-Cl-cAMP 186  
9-*cis* retinoic acid 1561
- $\alpha$ -interferon 1236  
 $\alpha$ -particle emitter <sup>213</sup>Bi 2086  
acute leukaemia 1160  
acute lymphoblastic leukaemia 707  
acyclovir 2079  
adducts 1380  
adenocarcinoma 739, 1384, 1853  
adenocarcinoma of lung 771  
adenocarcinoma of uterine cervix 1032  
adenoid cystic carcinoma 1131  
adenoma-carcinoma sequence 312  
adenovirus 171, 1610  
adhesion, Rho-GTPases 1800  
adjuvant 1005  
adjuvant chemotherapy 56  
adjuvant therapy 242, 1656, 1893  
adoptive immunotherapy 817  
advanced 839  
advanced breast cancers 861  
advanced cancer 254, 1050  
advanced gastric cancer 453  
advanced NSCLC 1996  
advanced soft tissue sarcoma 1639  
age 1880  
aggressive NHL 850  
AKT 1420, 1735, 1808  
aldehydes 111  
allelic imbalance 1025  
aluminium disulphonated phthalocyanine 788  
American Joint Committee on Cancer stage IV 699  
amputation 1012  
androstenediol 1399  
aneuploidy 558  
angiogenesis 359, 498, 1149, 1174, 1293, 1391  
angiogenesis inhibitor 1645  
anthracycline 37  
antibodies 1610  
antibody engineering 1200  
antibody processing 1500  
antibody therapy 1500  
antiinflammatory drug 525  
antimelanoma activity 297  
antioestrogen 1703  
antisense 1166  
antitumour activity 1624  
anxiety 893  
Apaf-1 1089  
APC 1155, 1571  
APE/ref-1 1166  
APITDI 1119  
apoptosis 164, 178, 195, 305, 359, 537, 580, 589, 803, 1195, 1358, 1372, 1405, 1614, 1718, 1726, 1808, 1842, 1931, 2026, 2094  
ASCI 985  
aspirin 525  
ATM 783  
attendance 1887  
audit 248  
autoimmunity 1508  
axillary clearance 651
- $\beta$ -catenin 153, 1571  
Bacillus Calmette-Guérin 607  
base excision repair 1166  
Bax 1372, 1931  
B-cell lymphoma 1500  
Bcl-2 164, 171  
Bcr-Abl 1735  
behaviour therapy 1050  
belief in curability 254  
benign prostatic disease 1755  
benzo[*a*]pyrene 1380  
biliary tract cancer 1769  
biological 530  
biomarkers 129, 725, 1190  
birth weight 519, 1666  
bisphosphonates 803, 1703  
bladder cancer 607, 844, 1025, 2034  
BMS-184476 213  
body mass index 519  
bone marrow 1813  
bone tumour 1858  
borderline tumours 1829  
brain 374  
brain metastases 639, 829  
brain tumour 1678  
BRCA 1787  
BRCA1 1155, 1910  
BRCA1/2 1580  
BRCA2 1155, 1910  
breakage-fusion-bridge cycle 327  
breast 237, 954  
breast cancer 69, 96, 99, 178, 233, 242, 277, 305, 413, 476, 512, 519, 618, 639, 651, 868, 873, 879, 959, 1063, 1190, 1251, 1263, 1308, 1532, 1591, 1687, 1694, 1813, 1893  
breast cancer cells 1703  
breast cancer family history 884  
breast cancer incidence 861  
breast cancer mortality 861  
breast cancer screening 861  
breast density 233  
breast neoplasms 644, 1482, 1666, 1795  
breast radiography 1795  
breast radiography, quality assurance 1795  
C595 monoclonal antibody 2086  
CA IX 1301, 1947  
cachexia 408  
calcitriol 1425  
camptothecin 50  
cancer 56, 111, 504, 907, 1269  
cancer awareness 62  
cancer cachexia 1742  
cancer chemoprevention 1213  
cancer genetics 1829  
cancer registries 1663  
cancer risk 1525  
cancer screening 1795  
cancer services 62  
cancer survival 1663  
cancer symptom management 822  
cancer testis antigen 141  
cancer-related fatigue 822  
cancer-testis antigen 1566  
capecitabine 613, 834, 839, 1019, 1763, 2005  
carbohydrate antigen 15-3 873  
carboplatin 213, 627, 683, 1038, 1651  
carcinoembryonic antigen 873  
carcinoembryonic antigen-related cell adhesion molecule 6 1384  
carcinogenesis 119, 195, 633  
carcinoma 1515  
cardiotoxicity 45  
case-control study 1829  
caspases 1358, 1726  
cathine 1726  
cathinone 1726  
caveolin 959  
CCI-779 1420  
CD10 1342  
CD20 antigen 1500  
CD4 + 541  
CD8 + 541  
CD95 164  
CDH13 1139  
CDKN2A 1112  
cDNA microarray 1543  
cell cycle 195, 803, 1842, 2026  
cell cycle arrest 1364  
cell proliferation 1181, 2042  
central nervous system tumour 923  
central venous access port devices 1045  
centrosome 327  
ceramide 1821  
cerebral blood volume 374  
cervical cancer 84, 1032, 2056  
cervical neoplasia 942  
cervical screening 942  
cervical smear test result 1887  
cervix 1269, 1902, 2063  
cervix cancer 106  
cervix neoplasms 530  
cervix uteri 935  
cetuximab 418  
CGH 775, 2063  
chemoprevention 381, 1364  
chemoradiation therapy 1025  
chemoradiotherapy 11, 673  
chemoresistance 434  
chemosensitivity 666  
chemotherapy 18, 476, 695, 839, 844, 1005, 1038, 1239, 1425, 1428, 1614, 1639, 1758, 1763, 1769  
childhood ALL 913  
childhood cancer 37, 923, 1905  
childhood leukaemia 916  
children 425  
chromosome 16 1591  
chromosome 1p 1105  
chromosome 3p 1143  
chromosome 9q 760  
chromosome aberrations 775  
chromosome instability 327  
chromosome rearrangements 753  
cigarette smoke 111  
cigarette smoking 1280, 1525  
CIN1 2056  
CIN3 942  
circulating tumour cells 1813  
cisplatin 18, 589, 683, 1614, 2005  
classic Kaposi's sarcoma 1261  
clinical trial 1645  
clodronate 1703  
clonality 775  
clusterin 1842  
c-Myc 1372  
cohort study 942  
colon neoplasms 1718  
colorectal cancer 153, 339, 344, 381, 839, 980, 1015, 1428, 1434, 1453, 1711, 1758, 1931  
colorectal carcinoma 312  
colorectal liver metastases 205

- combination chemotherapy 1032, 1472  
 communication 254  
 comparative study 23  
 complementary therapies 1482  
 consultant volume 459  
 conversion 1269  
 cost of illness 77  
 cost-benefit analysis 23  
 cost-effectiveness 84  
 Cox regression 923  
 COX-2 633  
 CpG island 707  
 CPT-11 482, 1205, 1434, 1442, 1447  
 C-reactive protein (CRP) 205, 699, 1063, 1236, 1755, 1993  
 cross-sectional 1575  
 CSF 219  
 CT scan 850  
 CTCF 1591  
 CTL 398, 817  
 cultural competence 62  
 cumulative incidence 1229  
 cure models 225  
 CXCR1 1970  
 CXCR2 1970  
 cyclin D 1239  
 cyclin D1 153  
 cyclin E 1239  
 cyclo-oxygenase 1213  
 cyclooxygenase 1015  
 cyclooxygenase-2 359  
 cyclophosphamide 1466  
 CYFRA 21-1 873  
 CYP1A1 1380  
 CYP1B1 966, 1380  
 cystadenocarcinoma 2048  
 cytochrome P450 333  
 cytokeratin 18 739  
 cytokeratin 5 739  
 cytokeratin-19 1813  
 cytokeratin-19 fragments 873  
 cytokine 607  
 cytokine receptors 1993  
 cytology 558  
 cytoskeleton 1327  
 cytotoxic chemotherapy 1561  
 cytotoxic T lymphocyte 287  
 cytotoxicity 1195, 2026  
  
 DARPP-32 119  
 database 355  
*DBCCR1* 760  
 DCIS 564  
 DDS 1775  
 DEC1 954  
 decision-making 855  
 dendritic cells 1656  
 depression 900  
 deprivation 1063  
 desmoplastic reaction 1316  
 development 258  
 DHA-paclitaxel 1651  
 diagnosis 714, 1633  
 diet 1624  
 dietetics 447  
 differential expression 1160  
 differentiation 258, 1143  
 dihydropyrimidine dehydrogenase 1245  
 direct IAP-binding protein with low pI 1349  
*Dkk-3* 707  
 DNA 1066  
 DNA adducts 333  
 DNA damage checkpoint 1669  
 DNA hypermethylation 270  
 DNA methylation 703, 760  
 DNA replication licensing 262, 714  
 DNA vaccine 688  
 DNA-PKcs 1735  
 docetaxel 18, 618, 1425, 1466, 1996  
 doublet regimens 489  
 Down syndrome 1866  
 doxorubicin 1775  
 doxorubicin (adriamycin) 1800  
 drug resistance 1166, 1405, 1800  
 dysplasia 1081  
  
 early discharge 651  
 ECarboF 1472  
 economic burden 77  
 educational attainment 923  
 efficacy 1434  
 EGFR 418, 430, 1066, 1301, 2026, 2042  
 EGFR family 1532  
 EGFR-1 470  
 elderly 1453  
 elderly NSCLC patients 489  
 elongation factor-1 delta 282  
 endocytosis 270  
 endometrial cancer 720, 1808  
 endosonography 23  
 enterolactone 99  
 epidemiology 512, 525, 644, 935, 1261, 1275, 1829  
 epidermal growth factor receptor 208, 795  
 epidermal growth factor receptor tyrosine kinase inhibitor 208  
 epirubicin 18, 45, 1466  
 EPR effect 1775  
 Epstein-Barr virus 572  
 ER gene expression 1694  
 ER- $\beta$  1687  
 ErbB2 1200, 1916  
 ERK 589  
 erlotinib 418  
 ET-1 434  
 ET<sub>A</sub>R 434  
 ET<sub>B</sub>R 434  
 etoposide 659, 1038, 1842  
 Ets transcription factors 1308  
 evaluation 935  
 Ewing's sarcoma 225, 1858  
 experimental therapeutics 1808  
 expression 1515  
 extracellular domain 430  
 extracellular matrix 1327  
 extracellular matrix proteins 1964  
 family cancer history 1575  
 family history 96, 929  
 Fas 164  
 Fas receptor 1718  
 Fas-associated phosphatase-1 1718  
 FBP 270  
 feasibility 627  
 FHIT 2056  
 Fhit deficiency 1669  
 Fhit protein 1669  
 first pregnancy 512  
 first-line chemotherapy 1466  
 FISH 558  
 flavonoids 1364  
 fludarabine 695  
 folic acid 453  
 follicular 695  
 follicular thyroid tumours 732  
 fractionated cisplatin 844  
 fractionated irradiation 1543  
 fragile histidine triad gene (*FHIT*) 1571  
 fragile sites 753  
 free radicals 111  
 full length TRAIL 171  
 function 1858  
 functional analysis 1287  
  
 galectin-3 1096  
 ganciclovir 2079  
 gangliosides 389  
 gastric adenocarcinoma 11  
 gastric cancer 1139, 1245, 1924  
 gastric cancer 1335  
 gastric carcinoma 18, 1342  
 gastrointestinal cancer 834  
 GD1b synthase 389  
 gefitinib 208, 418, 1964, 2026  
 gemcitabine 482, 489, 673, 844, 1166, 1763  
 gemcitabine ovarian cancer 627  
 Geminin 262  
 gene amplification 725  
 gene expression 666, 1015, 1089, 1597  
 gene polymorphism 1551  
 gene profiling 200  
 gene therapy 817, 1610, 2079  
 gene-environment interaction 339  
 genetic counselling 1580  
 genetic pathway 312  
 genetic risk 1575  
 Gleason score 1755  
 glioblastoma 1195  
 glioma 374, 745, 1174, 1656  
 glioma survival 1678  
 glycolysis 2094  
 granulocytes 1316  
 growth 519  
 growth factor receptor 666  
 growth inhibition 580  
 growth pattern 1293  
 growth regulation 1955  
*GSTP1* 985  
 guidelines 4  
 Guthrie cards 913  
 haemoglobin oxygen saturation 788  
 haptoglobin 129  
 haptoglobin-1 precursor (HAP1) 129  
 Hashimoto's thyroiditis 1096  
 HCC 1964  
 HD 850  
 head and neck cancer 1477  
 head and neck neoplasms 124  
 head and neck squamous cell carcinoma 2005  
 health anxiety 893  
 height 519  
*Helicobacter pylori* 929  
 heparin 30  
 hepatoblastoma 972  
 hepatocarcinogenesis 1955  
 hepatocellular carcinoma 753, 1561  
 HER-2 430, 795  
 HER2/neu 959, 1195, 1308  
 HER3 2034  
 HER4 2034  
 Herceptin 1190  
 heregulins 2034  
 herpes simplex virus thymidine kinase 2079  
 herpes virus 913  
 herpes zoster 1275  
 hierarchical cluster analysis 319  
 hierarchical clustering 775  
 HIF-1 $\alpha$  954  
 high risk 69  
 high-dose 5-fluorouracil 453  
 high-grade gliomas 425, 1038  
 histocompatibility antigens class II 1500  
 histological subtype 1143  
 HLA-A24 287  
 HLH 1990  
*hMLH1* 1155  
*hMSH2* 1155  
 HNPCC 1155, 1287  
*HO-1* 1551  
 Hodgkin's disease 572  
 homeodomain 258  
 hormonal receptor 959  
 hormone replacement therapy 644  
 hospital teams 248  
 hospital volume 459  
 household and family 907  
 HPV 942, 1269  
 HPV16 2056  
 human 1880  
 human bronchial epithelial cells 333  
 human gastric mucin 1342  
 human melanoma cell lines 297  
 human papillomavirus 84  
 human telomerase reverse transcriptase 972  
 hypersensitive patients 1251  
 hypersensitivity 213  
 hypoalbuminaemia 205  
 hypopharynx 258  
 hypoxia 374, 954, 1181, 1947

- I $\kappa$ B 381  
 Id-1 2042  
 IFN-gamma 688  
 IGF1 1735  
 IGF-binding proteins 1525  
 IL-6 1074, 1335  
 IM862 1645  
 immune escape 1718  
 immune response 688  
 immune therapy 1880  
 immunohistochemistry 119,  
     434, 552, 1342, 1532, 1556,  
     1591  
 immunotherapy 398, 607, 688,  
     1200, 1656  
 inadequate 1887  
 incidence 77, 916, 1275  
 indicator 972  
 induction 1624  
 infections 1866  
 inflammatory cytokines 1993  
 information needs 855  
 information services/\*stan-  
     dards/utilisation 1482  
 informative censoring 1229  
 inhibition of cell proliferation  
     2094  
 insulin-like growth factors 1525  
 integrins 1327  
 interaction 233  
 interferon 164  
 interferon-alpha 621  
 interleukin-6 1755  
 interleukin-8 1327  
 interleukin-8/CXCL8 1970  
 internet 1482  
 internet/\*standards/utilisation  
     1482  
 interstitial therapy 441  
 interventional radiologists  
     1045  
 intestinal lesions 1571  
 intestinal polyps 1571  
 intratumoral CD8 + T cells  
     1711  
 invasion 745, 1308, 1384, 1556,  
     1800  
 iodine 544  
 ionising radiation 2026  
 IRES vector 1842  
 Iressa 208  
 irinotecan 659, 678, 1245, 1434,  
     1447, 1453  
 ischaemia reperfusion injury  
     788  
  
 JACC study 929  
 JAK 1074  
  
 Kaplan–Meier estimate 1229  
 Khat 1726  
 Ki-67 262, 2018  
 KIT 2048  
 knowledge 855  
  
 lactate dehydrogenase (LDH)  
     699  
 Laminin-5 1964  
  
 laser capture microdissection  
     1096  
 late cardiac toxicity 37  
 leptomeningeal metastasis 219  
 leucovorin 1442, 1758  
 leukaemia 186, 1866  
 leukaemia cells 1726  
 LightCycler 972  
 lignan 99  
 limb-sparing surgery 1012  
 LINE retrotransposons 985  
 liposomal doxorubicin 1639  
 liquid-based cytology 84  
 liver enzymes 205  
 liver perfusion 1610  
 Lokich 1447  
 longitudinal 907  
 long-term response 1873  
 loss of heterozygosity 760, 1105,  
     1143  
 loss to follow-up 106  
 lower extremity 1858  
 lower extremity sarcomas 1012  
 lung 1515  
 lung adenocarcinoma 1143  
 lung cancer 208, 537, 1149,  
     1280, 1970, 2018  
 lung carcinogenesis 1380  
 lymphangiogenesis 498  
 lymphatic metastasis 124  
 lymphoma 141, 695  
  
 MAG-CPT 50  
 MAGE 398  
 magnetic resonance imaging 23,  
     374  
 maintenance therapy 621  
 malignancy grade 644  
 malignant effusion 558  
 malignant melanoma 765  
 mammaglobin 1813  
 mammary carcinoma 1200  
 mammary gland 1372  
 mammography 413  
 mammography screening 242  
 MAPK 1405  
 mass screening 530, 900  
 maternal hypertension 1666  
 MCF-7 1821  
 MCF-7 cells 178  
 MCM 262  
 Mcm5 714  
 MDM2 1415  
 measles virus 572  
 medical oncology 900  
 MEK 589  
 melanoma 699, 803, 829, 1089,  
     1495  
 membrane transport 2079  
 menarche 519  
 mesoionic compounds 297  
 mesothelioma 9  
 Met expression 703  
 meta-analysis 2018  
 metabolism 1213  
 metabolites 333  
 metalloprotease inhibitor 30  
 metastases 1782  
  
 metastasis 359  
 metastatic 683  
 metastatic breast cancer 77,  
     1466  
 metastatic colorectal cancer  
     1447  
 metastatic lymph node 466  
 METH-2 1149  
 methotrexate 1428  
 methylation 707, 739, 771, 1131,  
     1149, 1335, 1835, 2071  
 methylselenol 195  
 MIC-A/B 1495  
 micelle 1775  
 microarrays 1112, 1160, 1614,  
     1924, 1931  
 MI-D 297  
 mismatch repair 1287  
 missing covariate data 4  
 mitogen-activated protein ki-  
     nase 178, 795  
 mitomycin C 834, 839, 1624  
 mitomycin C resistance 1669  
 mitosis 537  
 mitoxantrone 1005  
 MLL cleavage and rearrange-  
     ment 1990  
 MLPA 1155  
 MMP-9 1301, 1384  
 models 530  
 molecular markers 552  
 molecular staging 558  
 monitoring 873, 935  
 monochromatic synchrotron  
     radiation 544  
 monoclonal antibody 725, 1195  
 mortality 242, 1902  
 motility 1800  
 mouth 1551  
 MSH6 1287  
 MTAP 1112  
 m-TOR 1420  
 MUC1 1633  
 MUC-1 mucin 2086  
 MUC2 1342  
 MUC4 1633  
 MUC6 1342  
 mucin 1633  
 mucoepidermoid carcinoma  
     1131  
 multicenter trial 45  
 multimedia 855  
 multimodality treatment 666  
 multiple breast carcinomas 775  
 multiple myeloma 1873  
 multiple testing 1160  
 multivariate analyses 1711  
 muscle 408  
 muscle wasting 1742  
 mutation 355, 2048  
 myoepithelial cells 564  
  
 natural product 1405  
 need for control 254  
 neoadjuvant chemotherapy  
     2012  
 neoplasm 1551  
 neoplasm seeding 9  
  
 nested case-control study 929  
 neuroblastoma 389, 1112, 1119,  
     1205, 1835  
 NF- $\kappa$ B 381, 1742  
 NK 1495  
 NK911 1775  
 NKG2D 1495  
 NKT cells 1880  
 nonangiogenic growth 1293  
 non-small-cell lung cancer 430,  
     771, 1293, 1993  
 nonsteroidal anti-inflammatory  
     drug 153  
 NQO1 1624  
 NSAIDs 381  
 NSCLC 171, 482, 1301  
 nuclear factor I-B3 1112  
 nuclear sites 916  
 nucleus 537  
 nude mice 1364  
 nurse led 651  
 nutrition support 447  
  
 oesophageal cancer 714, 1139,  
     1543, 1556  
 oesophageal neoplasms 282  
 oesophageal squamous cell car-  
     cinoma 119  
 oestrogen receptor 1703, 2012  
 oestrogen receptor beta 1694  
 oestrogens 178, 644, 1399  
 oestrone sulphate 1399  
 older people 907  
 oligoastrocytoma 1105  
 oligodendroglioma 262, 1105  
 oral 111, 1459  
 oral carcinoma 760  
 oral chemotherapy 613  
 oral contraceptives, ovarian  
     cancer 1910  
 oral squamous cell carcinoma  
     1074  
 oral submucous fibrosis 1551  
 organotypic brain slice cultures  
     745  
 osteosarcoma 1858  
 outpatient 844  
 ovarian cancer 129, 621, 725,  
     1614, 1829, 1916, 2042  
 ovarian carcinoma 470  
 ovarian neoplasms 2048  
 ovarian tumour 633  
 overall survival probability 1229  
 oxaliplatin 453, 1428, 1758, 1931  
 oxygenation 1181  
  
*p16<sup>INK4a</sup>* 771  
 p21 262, 1239  
 P450 reductase 966  
 p53 178, 1025, 1131, 1415, 1614,  
     1931  
 p53 activity 1488  
 p53 gene mutation 1081  
 p53 overexpression 1081  
 p73 1025  
 paclitaxel 45, 489, 1639  
 paclitaxel (taxol) 1800  
 PAH 333

- PAI-1 564  
 palliative 1005  
 palliative care 248, 900, 907, 1050  
 palliative radiotherapy 829  
 pancreatic cancer 459, 673, 1166, 1316, 1327, 1384, 1633  
 pancreatic cancer cell lines 2086  
 pancreatic tumours 2086  
 papillary carcinoma of the thyroid 703  
 papillomavirus 2063  
 parathyroid hormone-related protein (PTHrP) 287  
 PAS domain 141  
 pathological response 2012  
 pathology 23  
 patient survival 2034  
 pattern of failure 11  
 PAX8 732  
 PC3 cells 1358  
 PCR 913  
 PCR–SSCP 312  
 PDGFRA 2048  
 pegylated liposome 366  
 pentose cycle 2094  
 peptides 287, 1488  
 performance status 1236, 1453  
 perfusion 1181  
 peritoneal cytology 720  
 persistence 1269  
 PET scan 850  
 pheochromocytoma 1835  
 pharmacogenetics 344, 678  
 pharmacokinetics 50, 1434, 1769, 1775  
 phase I 1459, 1651  
 phase I study 1032  
 phase I trial 1019  
 phase II study 1032, 1769  
 photodynamic therapy 441, 788  
 phyto-oestrogen 99  
 PI3K pathway 1420  
 pimonidazole 1947  
 place of death 907  
 platinum therapy 344  
 polygenic model 1580  
 polymeric 50  
 polymorphisms 344, 339, 783  
 population-based cohort study 923  
 population-based studies 1263  
 positron emission tomography 2079  
 postmenopausal 1666  
 PPAR $\gamma$  633, 732  
 predictive 1239  
 predictive factors 1263  
 predictive genetic testing 1787  
 predictive marker 1025  
 prenatal origin 913  
 preneoplasia 1515  
 preoperative 434  
 preoperative breast biopsy 1782  
 preoperative radiotherapy 1019  
 pretreatment parameters 1873  
 prevalence 1575  
 primary vaginal and cervical cancers 319  
 prodrug 366  
 progesterin 644  
 prognosis 119, 237, 277, 430, 466, 470, 498, 552, 720, 829, 972, 1275, 1293, 1556  
 prognostic factors 96, 219, 282  
 prognostic index 829  
 prognostic marker 1391  
 prognostic models 4  
 prolactin 305  
 proliferative factor 2018  
 promoter methylation 1597  
 promoter polymorphism 765  
 pro-peptide 1955  
 prospective study 99  
 prostate 195, 1842  
 prostate cancer 287, 541, 580, 688, 855, 1005, 1358, 1425, 1472, 1755  
 prostate cancer susceptibility 783  
 prostate neoplasm 1853  
 prostate-specific antigen 688, 1853  
 prostatic intraepithelial neoplasia 739  
 proteasome expression 1742  
 protein degradation 408  
 protein expression 319  
 protein kinase A 186  
 protein synthesis 408  
 protein–protein interaction 1415  
 proteomics 129  
 proto-oncogene 282  
 psychological distress 504, 884  
 psycho-oncology 504  
 psychosocial 879  
 psychosocial aspects 504  
 psychosocial functioning 855  
 psychosocial interventions 1050  
 psychosocial issues 1787  
 PTEN 1420, 1808  
 PTGS2/COX2 339  
 purging 186  
 pyridoxal 5'-phosphate 1508  
 pyridoxal phosphatase 1508  
 Q-TWiST 1893  
 quality assurance 248  
 quality assurance, health care 1482  
 quality of life 56, 69, 1012, 1050, 1858, 1893, 1996  
 quality-adjusted survival 1893  
 quantitative real-time PCR 282  
 quantitative RT–PCR 1316  
 quercetin 1213  
 quinazoline 1066  
 radiation 868  
 radiation dose enhancement 544  
 radiation oncology 447  
 radiation therapy 1678  
 radical prostatectomy 1853  
 radioimmunoconjugate 2086  
 radioresistance 1543  
 radiosensitiser 366  
 radiosensitivity 666  
 radiosensitiser 673  
 radiotherapy 9, 23, 544, 868, 1239, 1251  
 Rapamycin 1420  
 RAR antagonists 580  
 RARB2 985  
 real-time RT-PCR 333, 1924  
 reassurance 893  
 receptor status 644  
 record linkage 92  
 rectal cancer 1019  
 rectal neoplasm staging 23  
 rectal neoplasms therapy 23  
 recurrence 2063  
 recurrence pattern 1342  
 recurrent head and neck cancer 441  
 redox metals 111  
 reflectance spectroscopy 788  
 registry 923  
 relative excess risk of death 1263  
 relative survival 1263, 1663  
 remission 893  
 renal cancer 1236  
 renal cell cancer 1645  
 renal cell carcinoma 164, 327, 966, 1349, 1763  
 reporting 4  
 resection 459  
 resistance 1205  
 response prediction 666  
 restaging 850  
 resveratrol 178, 333, 1380  
 retinoic acid 389  
 retinoic acid receptors 580  
 retroviral vector 1488  
 review 237  
 ribose synthesis 2094  
 rice bran 1364  
 risk 92, 1275  
 risk counselling 884  
 risk factors 45, 233  
 risk management 1787  
 risk modifiers 1580  
 ROC curve 1160  
 RT–PCR 200, 1813  
 S-1 1245, 1769  
 S100 739  
 S100A2 1515  
 safety 1434  
 saliva 111  
 salvage chemotherapy 659  
 sarcoma 237  
 satisfaction 884  
 satisfaction with information 1887  
 scaffold protein 1488  
 screening 69, 84, 413, 935, 1902  
 SDHB 1835  
 second line 659, 1996  
 second malignancy 868  
 second malignant neoplasm 1905  
 second mitochondria-derived activator of caspases 1349  
 second-line chemotherapy 482, 1442  
 selenium 195  
 selenomethionine 195  
 seminoma 683  
 sensitive relapse 659  
 sentinel lymph-node biopsy 124  
 sentinel node 1782  
 sequential paclitaxel 627  
 SEREX 141  
 serine protease 725  
 serology 1269  
 serous 2048  
 serum antibody 1566  
 serum lipids 476  
 serum marker 699  
 sex difference 929  
 SF-36 879  
 SFRP1 985  
 shedding 1500  
 siRNA 1384  
 skin cancer 1604  
 SLIT1 2071  
 SLIT3 2071  
 small GTPases 270  
 small molecule 1415  
 small-cell lung cancer 659  
 smoking 512  
 SN-38 678  
 socioeconomic status 879  
 SOCS-1 1335  
 solid tumours 1459  
 somatic 355  
 South Asian 62  
 southern Sardinia 1261  
 SPARC 1924  
 specialisation 459  
 sperm protein 17 1597  
 SRC-1 1687  
 stable isotope-based dynamic metabolic profiling (SIBDMAP) 2094  
 stage 720  
 stage IV breast cancer 77  
 standards 248, 1477  
 Stat3 1074, 1335  
 state anxiety 1887  
 statistical methods 1663  
 steroid sulphatase 1399  
 steroids 525  
 stomach cancer 929  
 stool 980  
 stromal macrophages 498  
 subcutaneous fibrosis 1251  
 sunlight 1604  
 surgery 23  
 survival 4, 106, 237, 459, 541, 720, 1236, 1275, 1453, 1477  
 survival analysis 1293  
 survivin 537  
 synergy 171  
 systematic review 1050, 2018



- systemic inflammatory response 1063, 1236
- TAA 398
- Tabar classification 233
- tamoxifen 476, 1251, 1694
- targeted therapy 795
- taxanes 213, 1005, 1651
- TCC 398
- telomerase 972
- telomere 327
- temozolomide 425
- TFIID 1119
- TGCT 589
- TGF- $\beta$  1316
- Tg-mRNA 200
- thalidomide 1873
- therapeutic intervention 966
- therapy 1633
- thymidylate synthase 1245
- thyroglobulin 200
- thyroid cancer 1096
- thyroid carcinoma 200
- tissue array 537
- tissue inhibitor of matrix metalloproteinase 3 (TIMP-3) 1556
- tissue microarray 1089, 1532
- T-lymphocytes 541
- topoisomerase I inhibitor 1459
- topoisomerase II $\alpha$  1038
- total PSA 1755
- toxicity 1453
- TP53 1119, 1916
- transcription factor 1566
- transforming growth factor  $\alpha$  1955
- transgenic mice 1372
- transitional cell carcinoma 552
- transudate 558
- trastuzumab 639, 959
- treatment choice 56
- treatment-related leukaemia 1990
- trends 1902
- triazene 1066
- troglitazone 1561
- tumorigenesis 1372, 1566
- tumour growth 1964
- tumour immunity 1711
- tumour M2-PK 980
- tumour marker 699
- tumour necrosis factor 30
- tumour prestages 1955
- tumour progression 1349, 1694
- tumour screening 980
- tumour size 277, 959
- tumour suppressor gene 753, 1105, 1571
- tumour vaccination 1656
- tumour volume 205
- tumours 237, 374, 954, 966, 1947, 2071
- tyrosine kinase 1735
- tyrosine kinase inhibitor 1174, 1391
- Tyrphostin AG1024 1735
- UFT 613, 1758
- UGT1A1 678
- ulcerative colitis 1081
- underexpression 732
- uPAR 564
- urban and rural area 1261
- urokinase plasminogen activator (uPA) 1308
- uterine cervical cancer 466
- utility 1893
- UVC resistance 1669
- uvea 1495
- vaccine 817
- vasculature 1181
- VDR 765
- VEGF 219, 498, 1174, 1181, 1391
- VEGF-C 466
- VEGFR2 1391
- venous thromboembolism 92
- vinorelbine 489
- vitamin D 1425
- waiting times 1477
- website 355
- weekly schedule 1996
- worry 1787
- WWOX gene expression 753
- xenograft 1205
- X-linked inhibitor of apoptosis 1349
- XR11576 1459
- XRCC1 1604
- ZD1839 208
- ZD6474 1174
- zinc-finger protein 1566